Atika Capital Management LLC Roivant Sciences Ltd. Transaction History

Atika Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$10.36 - $11.74 $1.4 Million - $1.58 Million	-134,980 Reduced 25.23%	400,000 $4.23 Million
Q1 2024 May 14, 2024	SELL	$9.87 - $11.8 $2.02 Million - $2.42 Million	-205,000 Reduced 27.7%	534,980 $5.64 Million
Q4 2023 Feb 13, 2024	BUY	$8.38 - $11.58 $1.63 Million - $2.26 Million	194,980 Added 35.78%	739,980 $8.31 Million
Q3 2023 Nov 13, 2023	BUY	$9.76 - $13.19 $1.43 Million - $1.93 Million	146,500 Added 36.76%	545,000 $6.37 Million
Q2 2023 Aug 11, 2023	SELL	$7.09 - $10.08 $613,285 - $871,920	-86,500 Reduced 17.84%	398,500 $4.02 Million
Q1 2023 May 12, 2023	SELL	$6.92 - $9.98 $519,000 - $748,500	-75,000 Reduced 13.39%	485,000 $3.58 Million
Q4 2022 Feb 13, 2023	BUY	$3.36 - $7.99 $1.88 Million - $4.47 Million	560,000 New	560,000 $4.47 Million

311

508M

1.26M

2.52M

Ticker ROIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 704,382,976
Market Cap $8.95B
Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Atika Capital Management LLC with notifications on news.